Status:
COMPLETED
Retrospective Evaluation of Commercial Spacers in Prostate Cancer Patients
Lead Sponsor:
BioProtect
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
Assessment of efficacy and safety of implantable spacers when used to reduce the radiation dose delivered to the organs at risk in prostate cancer patients undergoing radiotherapy.
Detailed Description
Multi-center, retrospective, observational study for assessment of rectal dose reduction following implantation of the BioProtect Balloon Implant System
Eligibility Criteria
Inclusion
- \- Males at least 18 years of age, who have undergone radiation therapy with implantable spacers
Exclusion
- Patients whose clinical and pathological data are not available.
- Patients have been histologically diagnosed with invasive adenocarcinoma that is extracapsular with posterior extension
Key Trial Info
Start Date :
June 18 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2022
Estimated Enrollment :
175 Patients enrolled
Trial Details
Trial ID
NCT05354427
Start Date
June 18 2020
End Date
January 1 2022
Last Update
September 16 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Maria Skłodowska, Curie (MCMCC)
Warsaw, Poland
2
Cuf Porto institution
Porto, Portugal